GlassScriptPhysician profile
Damon Daniels
NPI 1235104464
$15,309.74
in general payments reported to CMS, 2019-2025
71 companies · $1,841 in 2025
The $1,841 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,545 · 2020: $3,263 · 2021: $2,519 · 2022: $2,363 · 2023: $2,124 · 2024: $1,655 · 2025: $1,841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,574 · Education: $46.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,573.56 |
| Education | $46.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,807.20 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $1,350.26 | 2019-2023 | |
| Pfizer INC. | $1,120.42 | 2019-2025 | |
| Novo Nordisk INC | $839.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $794.07 | 2019-2025 | Repatha, Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $735.38 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Lilly USA, LLC | $686.83 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Medicure Pharma INC. | $604.22 | 2020-2023 | Zypitamag |
| Sanofi-Aventis U.S. LLC | $596.43 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $574.87 | 2019-2025 | Jardiance |
| Abbvie INC. | $543.21 | 2020-2025 | Qulipta, Linzess, Viberzi |
| Global Blood Therapeutics, INC. | $487.42 | 2020-2022 | |
| Abbott Laboratories | $439.32 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $345.22 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $325.31 | 2021-2025 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Renalytix Ai, INC. | $323.75 | 2022-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Amarin Pharma, INC. | $276.56 | 2019-2022 | |
| Astellas Pharma US INC | $276.31 | 2019-2024 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $249.11 | 2019-2025 | Xifaxan, Trulance |
| Dexcom, INC. | $234.22 | 2020-2024 | Dexcom G6 Transmitter |
| Alnylam Pharmaceuticals INC. | $207.97 | 2019-2023 | Onpattro |
| Esperion Therapeutics, INC. | $171.08 | 2020-2025 | Nexletol |
| Fidia Pharma USA INC. | $167.01 | 2022-2023 | Triluron, Hymovis, Hym/Hyn |
| Emmaus Medical, INC. | $152.77 | 2022-2025 | Endari |
| Merck Sharp & Dohme LLC | $138.18 | 2019-2024 | Capvaxive |
| Corcept Therapeutics | $133.83 | 2021-2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $132.15 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $117.40 | 2019-2025 | Spravato |
| Allergan, INC. | $112.40 | 2020 | |
| Exact Sciences Corporation | $111.03 | 2023-2025 | Cologuard Collection Kit |
| Ardelyx, INC. | $104.52 | 2025 | Ibsrela |
| Arbor Pharmaceuticals, INC. | $79.42 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $70.24 | 2019-2021 | |
| Alfasigma USA, INC. | $68.50 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $67.32 | 2025 | Gemtesa |
| Eisai INC. | $62.50 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $54.86 | 2023-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.16 | 2024-2025 | Caplyta |
| Recor Medical INC | $51.45 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Biohaven Pharmaceutical Holding Company LTD. | $49.35 | 2022 | |
| Sunovion Pharmaceuticals INC. | $44.34 | 2022 | |
| Edwards Lifesciences Corporation | $39.14 | 2021-2022 | |
| Phadia US INC. | $35.68 | 2021-2025 | Immunocap |
| Hikma Pharmaceuticals USA | $34.33 | 2022 | |
| Paratek Pharmaceuticals, INC. | $31.61 | 2021 | |
| Antares Pharma, INC. | $29.64 | 2022-2023 | Tlando, Xyosted, Nocdurna |
| Ironwood Pharmaceuticals, INC | $28.53 | 2020 | |
| Shire North American Group INC | $27.81 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $27.15 | 2024 | Rexulti |
| Corvista Health, INC. | $25.40 | 2025 | Corvista System |
| Xeris Pharmaceuticals, INC. | $24.74 | 2022 | |
| Lundbeck LLC | $22.89 | 2023 | Vyepti |
| Bioventus LLC | $19.45 | 2020 | |
| Abiomed | $18.98 | 2025 | |
| Mannkind Corporation | $18.78 | 2019 | |
| Virtus Pharmaceuticals LLC | $17.25 | 2021 | |
| Qiagen, LLC | $16.44 | 2020 | |
| Idorsia Pharmaceuticals US INC | $16.02 | 2023 | Quviviq |
| Sanofi Pasteur INC. | $14.81 | 2020 | |
| Medtronic, INC. | $14.67 | 2024 | Intellis Adaptivestim |
| Indivior INC. | $14.37 | 2024 | Sublocade |
| Snap Diagnostics LLC | $13.46 | 2023 | Snap Diagnostics Study |
| Seqirus USA INC | $13.43 | 2021 | |
| Scynexis, INC. | $13.13 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.20 | 2021 | |
| Kaleo, INC. | $11.27 | 2019 | |
| Clarus Therapeutics INC. | $10.80 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damon Daniels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.